Earnings Call Summary | OrganiGram(OGI.US) Q2 2024 Earnings Conference
Earnings Call Summary | OrganiGram(OGI.US) Q2 2024 Earnings Conference
The following is a summary of the Organigram Holdings Inc. (OGI) Q2 2024 Earnings Call Transcript:
以下是Organigram Holdings Inc.（OGI）2024年第二季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Organigram reported increased cash position due to $124.6 million investment from BAT and a financing round that raised an additional $28.8 million.
Organigram's recreational net revenue increased by 21% to a gross revenue of $57.4 million in Q2 2024. However, due to a decline in international sales, there was a slight contraction to a net revenue of $37.6 million—a 5% decrease.
The company reported a net loss of $27.1 million for Q2 2024 primarily due to lower gross margins and an increase in a fair value loss of derivative liability relating to BAT preferred shares.
Organigram's cash used in operating activities decreased by 54% to $9 million in Q2 fiscal 2024 compared to the same period in the previous year.
The company expects its positive adjusted EBITDA in fiscal 2024 to exceed that of fiscal 2023.
Organigram報告稱，由於英美菸草的1.246億美元投資以及一輪融資額外籌集了2880萬美元，現金狀況有所增加。
2024年第二季度，Organigram的娛樂淨收入增長了21％，達到5,740萬美元的總收入。但是，由於國際銷售下降，淨收入略有收縮至3,760萬美元，下降了5％。
該公司報告稱，2024年第二季度淨虧損2710萬美元，這主要是由於毛利率下降以及與英美菸草優先股相關的衍生負債的公允價值損失增加。
與去年同期相比，Organigram在2024財年第二季度用於經營活動的現金下降了54％，至900萬美元。
該公司預計，其2024財年的正調整後息稅折舊攤銷前利潤將超過2023財年的息稅折舊攤銷前利潤。
Business Progress:
業務進展：
Organigram announced strategic investments in Phylos Bioscience and Open Book Extracts and completed its first shipment of medical flower to Sanity Group in Germany and cannabis to 4C Labs for distribution in the U.K.
The company remains a leader in the domestic market, holding top positions in major product categories. New innovations like nano-emulsion technology for accurate dosage control and expanded THCV products are slated for launching.
Organigram is transitioning its Moncton facility to seed-based production, expecting to increase yields, reduce costs, and ensure more consistent and robust plant production.
The company is preparing for its national rollout with Greentank following the resolving of identified issues from their test launch.
Organigram is expected to show improved financial results in the second half of fiscal 2024 due to expanded international reach, business efficiency investments, and market share expansion.
The company aims to achieve positive cash flow from operations by the end of fiscal 2024 and plans to continue its expansion in international markets.
Organigram宣佈對Phylos Bioscience和Open Book Extracts進行戰略投資，並完成了向德國Sanity集團運送的第一批醫用花卉以及向4C Labs運送大麻以便在英國分銷的首批貨物。
該公司仍然是國內市場的領導者，在主要產品類別中名列前茅。新的創新即將推出，例如用於精確劑量控制的納米乳液技術和擴展的四氫大麻酚產品。
Organigram正在將其蒙克頓工廠過渡到以種子爲基礎的生產，預計將提高產量，降低成本，並確保更穩定、更穩健的植物生產。
在解決了試射中發現的問題後，該公司正在爲與Greentank的全國推廣做準備。
由於國際影響力的擴大、業務效率投資和市場份額的擴大，預計Organigram將在2024財年下半年顯示出改善的財務業績。
該公司的目標是到2024財年末實現正的運營現金流，並計劃繼續在國際市場擴張。
More details: OrganiGram IR
更多詳情： Organigram 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。